The Hooke Bio team recently attended the ADC Conference in London, joining researchers, industry leaders and innovators from across the antibody-drug conjugate (ADC) community.
The conference provided an excellent opportunity to discuss the latest advances in ADC development, preclinical testing and translational research, while connecting with organisations developing next-generation therapeutics.
Among the scientific highlights were presentations on in vitro bone marrow models for ADC toxicity assessment and the use of circulating tumour cells in liquid biopsy, demonstrating the continued move towards more predictive, human-relevant preclinical models.
Events such as the ADC Conference are invaluable for sharing knowledge, exploring new collaborations and understanding the evolving needs of the biopharmaceutical industry.
Hooke Bio provides human cell-based preclinical testing services alongside the Mera™ microphysiological system, supporting the development of innovative therapeutics with advanced in vitro models that generate meaningful, human-relevant data throughout the drug development journey.
We would like to thank everyone who visited us during the conference and look forward to continuing the conversations and building new collaborations.
